Premium
Management of anaphylaxis due to COVID‐19 vaccines in the elderly
Author(s) -
Bousquet Jean,
Agache Ioana,
Blain Hubert,
Jutel Marek,
Ventura Maria Teresa,
Worm Margitta,
Del Giacco Stefano,
Benetos Athanasios,
Bilo Beatrice Maria,
Czarlewski Wienczyslawa,
Abdul Latiff Amir Hamzah,
AlAhmad Mona,
Angier Elizabeth,
AnnesiMaesano Isabella,
AtanaskovicMarkovic Marina,
Bachert Claus,
Barbaud Annick,
Bedbrook Anna,
Bennoor Kazi S.,
Berghea Elena Camelia,
BindslevJensen Carsten,
Bonini Sergio,
BosnicAnticevich Sinthia,
Brockow Knut,
Brussino Luisa,
Camargos Paulo,
Caica G. Walter,
Cardona Victoria,
CarreiroMartins Pedro,
Carriazo Ana,
Casale Thomas,
Caubet JeanChristoph,
Cecchi Lorenzo,
Cherubini Antonio,
Christoff George,
Chu Derek K.,
Cruz Alvaro A.,
Dokic Dejan,
ElGamal† Yehia,
Ebisawa Motohiro,
Eberlein Bernadette,
Farrell John,
FernandezRivas Montserrat,
Fokkens Wytske J.,
Fonseca Joao A.,
Gao Yadong,
Gavazzi Gaëtan,
Gawlik Radoslaw,
Gelincik Asli,
Gemicioğlu Bilun,
Gotua Maia,
Guérin Olivier,
Haahtela Tari,
HoffmannSommergruber Karin,
Hoffmann Hans Jürgen,
Hofmann Maja,
Hrubisko Martin,
Illario Maddalena,
Irani Carla,
Ispayeva Zhanat,
Ivancevich Juan Carlos,
Julge Kaja,
Kaidashev Igor,
Khaitov Musa,
Knol Edward,
Kraxner Helga,
Kuna Piotr,
Kvedariene Violeta,
Lauerma Antti,
Le Lan T. T.,
Le Moing Vincent,
Levin Michael,
Louis Renaud,
Lourenco Olga,
Mahler Vera,
Martin Finbarr C.,
Matucci Andrea,
Milenkovic Branislava,
Miot Stéphanie,
Montella Emma,
MoraisAlmeida Mario,
Mortz Charlotte G.,
Mullol Joaquim,
NamazovaBaranova Leyla,
Neffen Hugo,
Nekam Kristof,
Niedoszytko Marek,
Odemyr Mikaëla,
O’Hehir Robyn E.,
Okamoto Yoshitaka,
Ollert Markus,
Palomares Oscar,
Papadopoulos Nikolaos G.,
Panzner Petr,
Passalacqua Giovanni,
Patella Vincenzo,
Petrovic Mirko,
Pfaar Oliver,
PhamThi Nhân,
Plavec Davor,
Popov Todor A.,
Recto Marysia T.,
Regateiro Frederico S.,
Reynes Jacques,
RollerWinsberger Regina E.,
Rolland Yves,
Romano Antonino,
Rondon Carmen,
Rottem Menachem,
Rouadi Philip W.,
Salles Nathalie,
Samolinski Boleslaw,
Santos Alexandra F.,
Sarquis Faradiba,
Sastre Joaquin,
M. G. A. Schols Jos,
Scichilone Nicola,
Sediva Anna,
Shamji Mohamed H.,
Sheikh Aziz,
Skypala Isabel,
Smolinska Sylwia,
Sokolowska Milena,
SousaPinto Bernardo,
Sova Milan,
Stelmach Rafael,
Sturm Gunter,
Suppli Ulrik Charlotte,
TodoBom Ana Maria,
ToppilaSalmi Sanna,
Tsiligianni Ioanna,
Torres Maria,
Untersmayr Eva,
Urrutia Pereira Marilyn,
Valiulis Arunas,
Vitte Joana,
Vultaggio Alessandra,
Wallace Dana,
WalusiakSkorupa Jolanta,
Wang DeYun,
Waserman Susan,
Yorgancioglu Arzu,
Yusuf Osman M.,
Zernotti Mario,
Zidarn Mihaela,
Chivato Tomas,
Akdis Cezmi A.,
Zuberbier Torsten,
Klimek Ludger
Publication year - 2021
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/all.14838
Subject(s) - medicine , anaphylaxis , asthma , allergy , covid-19 , pediatrics , intensive care medicine , immunology , disease , infectious disease (medical specialty)
Older adults, especially men and/or those with diabetes, hypertension, and/or obesity, are prone to severe COVID‐19. In some countries, older adults, particularly those residing in nursing homes, have been prioritized to receive COVID‐19 vaccines due to high risk of death. In very rare instances, the COVID‐19 vaccines can induce anaphylaxis, and the management of anaphylaxis in older people should be considered carefully. An ARIA‐EAACI‐EuGMS (Allergic Rhinitis and its Impact on Asthma, European Academy of Allergy and Clinical Immunology, and European Geriatric Medicine Society) Working Group has proposed some recommendations for older adults receiving the COVID‐19 vaccines. Anaphylaxis to COVID‐19 vaccines is extremely rare (from 1 per 100,000 to 5 per million injections). Symptoms are similar in younger and older adults but they tend to be more severe in the older patients. Adrenaline is the mainstay treatment and should be readily available. A flowchart is proposed to manage anaphylaxis in the older patients.